World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ChiCTR
Last refreshed on: 21 September 2020
Main ID:  ChiCTR2000036852
Date of registration: 2020-08-25
Prospective Registration: Yes
Primary sponsor: Shanghai Pulmonary Hospital
Public title: Establishment of an artificial intelligence screening and evaluation system based on multimodal imaging of pulmonary arterial hypertension: Study on clinical diagnosis model
Scientific title: Establishment of an artificial intelligence screening and evaluation system based on multimodal imaging of pulmonary arterial hypertension: Study on clinical diagnosis model
Date of first enrolment: 2020-10-01
Target sample size: Target condition:1000;Difficult condition:1000
Recruitment status: Pending
URL:  http://www.chictr.org.cn/showproj.aspx?proj=59939
Study type:  Diagnostic test
Study design:  Factorial  
Phase:  0
Countries of recruitment
Contacts
Name: Rong Jiang   
Address:  507 Zhengmin Road, Yangpu District, Shanghai, China 200433
Telephone: +86 13795493921
Email: listening39@163.com
Affiliation:  Shanghai Pulmonary Hospital
Name: JIN-Yun Shi   
Address:  507 Zhengmin Road, Yangpu District, Shanghai, China 200433
Telephone: +86 13671701139
Email: shijingyun89179@126.com
Affiliation:  Shanghai Pulmonary Hospital
Key inclusion & exclusion criteria
Inclusion criteria: 1. Signed informed consent voluntarily;
2. Those aged between 18 and 75 years (including 18 and 75 years old);
3. Right heart catheterization: mean pulmonary artery pressure (mPAP) >=25 mm Hg, pulmonary artery wedge pressure (PAWP) <=15 mmHg and pulmonary vascular resistance (PVR) >=3 wood units (240 dyn/s/CM5)
(1) idiopathic or hereditary PAH;
(2) PAH associated withconnective tissue disease;
(3) PAH associted with HIV infection;
(4) PAH associated with repaired congental heart disease;
(5) PAH associated with appetite inhibitor or toxin.

Exclusion criteria: 1) Other types of pH;
2) Patients refused to sign informed consent;
3) Lack of chest X-ray, CTPA and other electronic imaging data in our hospital.


Age minimum:
Age maximum:
Gender: Both
Health Condition(s) or Problem(s) studied
pulmonary arterial hypertension
Intervention(s)
Gold Standard:Right heart catheterization;Index test:multimodal imaging artificial intelligence screening and evaluation system;
Primary Outcome(s)
Automatic segmentation of pulmonary artery segments based on chest X-ray films;Calculation of aortopulmonary diameter ratio based on chest CT;Estimation of cardiothoracic ratio based on chest radiograph;Ratio of right ventricular and left ventricular short axis diameter on chest CT;Evaluation of cardiac morphology and function by CMR;
Secondary Outcome(s)
Secondary ID(s)
Source(s) of Monetary Support
none
Secondary Sponsor(s)
Ethics review
Status: Approved
Approval date: 25/08/2020
Contact:
Lin Zhang
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history